• Corpus ID: 41060906

NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).

@article{1993NTPTA,
  title={NTP Toxicology and Carcinogenesis Studies of Promethazine Hydrochloride (CAS No. 58-33-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies).},
  author={},
  journal={National Toxicology Program technical report series},
  year={1993},
  volume={425},
  pages={
          1-272
        }
}
  • Published 1993
  • Biology, Medicine
  • National Toxicology Program technical report series
Promethazine hydrochloride is a drug used for the management of allergic conditions, motion sickness and nausea, and as a sedative to (treat psychiatric disorders. This drug was nominated for testing by the Food and Drug Administration because of its widespread use in human medicine and because of lack of data on its potential carcinogenicity. Oral administration is the most common route of human exposure. Toxicology and carcinogenicity studies were conducted by administering promethazine… 
2 Citations
New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria
TLDR
It is suggested that DXP, AXPN, and TFP may modulate host cell pathways necessary for disease pathogenesis, and the broad applicability and potential use of nonantibiotic FDA-approved drugs to combat respiratory and gastrointestinal bacterial pathogens.
Onset of hepatocarcinogen‐specific cell proliferation and cell cycle aberration during the early stage of repeated hepatocarcinogen administration in rats
TLDR
It is suggested that it takes 28 days to induce hepatocarcinogen‐specific early withdrawal of proliferating cells from M phase due to disruptive spindle checkpoint function as evidenced by reduction of Ubd+ cells staying at M phase.